An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.)
injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling
diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue
medication to control symptoms in subjects with carcinoid syndrome.